# Phase 2 Lymphoma, Mantle-Cell trials recruiting: 55 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 55 trials in phase 2 for Lymphoma, Mantle-Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Lymphoma, Mantle-Cell trials: 55 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lymphoma-mantle-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 55
- Recruiting or not yet: 55
- Read on: November 19, 2026

## Trials

The 25 newest of 55, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944651 | Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma (MCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944651) |
| November 2, 2026 | NCT07910435 | Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial | University of Washington | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910435) |
| October 23, 2026 | NCT07892027 | Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma... | University of Michigan Rogel Cancer Center | Phase 2 | Recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma... | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892027) |
| October 2, 2026 | NCT07855016 | A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma | TransThera Sciences (Nanjing), Inc. | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma (MCL) | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855016) |
| September 2, 2026 | NCT07799220 | A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma | Memorial Sloan Kettering Cancer Center | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799220) |
| August 13, 2026 | NCT07763210 | Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma | Vanderbilt-Ingram Cancer Center | Phase 2 | Recruiting | Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell... | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763210) |
| August 5, 2026 | NCT07748364 | Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748364) |
| July 22, 2026 | NCT07719556 | Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Mantle Cell Lymphoma (MCL) | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719556) |
| July 6, 2026 | NCT07684950 | Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy | Henan Cancer Hospital | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma (MCL) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684950) |
| June 29, 2026 | NCT07673367 | Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma | Vanderbilt-Ingram Cancer Center | Phase 2 | Recruiting | Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673367) |
| May 6, 2026 | NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL | Miltenyi Biomedicine GmbH | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma (MCL) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569965) |
| March 10, 2026 | NCT07460362 | Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma | Peking University Third Hospital | Phase 2 | Recruiting | MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL) | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460362) |
| March 5, 2026 | NCT07453095 | Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy | Fondazione Italiana Linfomi - ETS | Phase 2 | Recruiting | Mantle Cell Lymphoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453095) |
| January 14, 2026 | NCT07341191 | Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy | Canadian Cancer Trials Group | Phase 2 | Recruiting | Mantle Cell Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341191) |
| December 16, 2025 | NCT07285590 | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 | Recruiting | Mantle Cell Lymphoma (MCL) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285590) |
| December 16, 2025 | NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment... | Mayo Clinic | Phase 2 | Recruiting | Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285044) |
| December 9, 2025 | NCT07272499 | Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease | Ruijin Hospital | Phase 2 | Recruiting | Mantle Cell Lymphoma (MCL) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07272499) |
| December 3, 2025 | NCT07261163 | Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Mantle Cell Lymphoma | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07261163) |
| October 6, 2025 | NCT07207785 | PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma | Fondazione Italiana Linfomi - ETS | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07207785) |
| October 3, 2025 | NCT07206264 | Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206264) |
| September 30, 2025 | NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | Ruijin Hospital | Phase 2 | Recruiting | Mantle Cell Lymphoma (MCL) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07199296) |
| July 24, 2025 | NCT07082686 | A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 | Recruiting | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07082686) |
| July 22, 2025 | NCT07077512 | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma | Sun Yat-sen University | Phase 2 | Recruiting | Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07077512) |
| June 19, 2025 | NCT07029737 | A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain | AstraZeneca | Phase 2 | Recruiting | Mantle-cell Lymphoma | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07029737) |
| June 4, 2025 | NCT07003295 | Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07003295) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Ruijin Hospital | 4 |
| Masonic Cancer Center, University of Minnesota | 2 |
| Fondazione Italiana Linfomi - ETS | 2 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 2 |
| Fred Hutchinson Cancer Center | 2 |
| Sun Yat-sen University | 2 |
| Henan Cancer Hospital | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| Vanderbilt-Ingram Cancer Center | 2 |
| City of Hope Medical Center | 2 |
| M.D. Anderson Cancer Center | 2 |
| Australasian Leukaemia and Lymphoma Group | 1 |
| Mayo Clinic | 1 |
| University of Washington | 1 |
| Canadian Cancer Trials Group | 1 |
| [Beijing InnoCare Pharma Tech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-innocare-pharma-tech-co-ltd) | 1 |
| Czech Lymphoma Study Group | 1 |
| Medical University of Vienna | 1 |
| University College, London | 1 |
| Dalian Medical University | 1 |
| Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 1 |
| Academic and Community Cancer Research United | 1 |
| University of Michigan Rogel Cancer Center | 1 |
| Peking University Third Hospital | 1 |
| University of California, San Francisco | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| China | 17 |
| Italy | 2 |
| Canada | 2 |
| Spain | 2 |
| Australia | 1 |
| Germany | 1 |
| Czechia | 1 |
| Austria | 1 |
| United Kingdom | 1 |
| Portugal | 1 |
| South Korea | 1 |
| Belgium | 1 |
| France | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [General dentistry practices in the United States](https://specstream.ai/data/businesses/general-dentistry-practices/united-states)
- [Packaging companies in the United States](https://specstream.ai/data/businesses/packaging-companies/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
- [Cancer treatment centers in the United States](https://specstream.ai/data/businesses/cancer-treatment-centers/united-states)
- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
- [Pediatric anesthesiology practices in the United States](https://specstream.ai/data/businesses/pediatric-anesthesiology-practices/united-states)
